Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Section 6 of 6

References

177 sources

  1. Alshekhlee et al. (2009) (opens in a new tab)
  2. American Academy of Neurology myasthenic crisis quality measure (opens in a new tab)
  3. Antozzi et al. (2025) (opens in a new tab)
  4. argenx VYVGART Hytrulo wholesale acquisition cost disclosure for Colorado prescribers (2026) (opens in a new tab)
  5. argenx VYVGART wholesale acquisition cost disclosure for Colorado prescribers (2025) (opens in a new tab)
  6. Barnett-Tapia et al. (2026) (opens in a new tab)
  7. Benatar et al. (2022) (opens in a new tab)
  8. Bkemv prescribing information (2026) (opens in a new tab)
  9. Bradhurst et al. (2026) (opens in a new tab)
  10. Bril et al. (2023) (opens in a new tab)
  11. Bruckman et al. (2024) (opens in a new tab)
  12. Carr et al. (2010) (opens in a new tab)
  13. Cartesian Therapeutics 2026 outlook press release (2026) (opens in a new tab)
  14. Cartesian Therapeutics AURORA first participant press release (2025) (opens in a new tab)
  15. Cartesian Therapeutics corporate presentation, May 2026 (2026) (opens in a new tab)
  16. Cartesian Therapeutics corporate presentation, November 2026 (2026) (opens in a new tab)
  17. Cartesian Therapeutics Form 10-K (2026) (opens in a new tab)
  18. Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
  19. Cartesian Therapeutics full year 2025 results (2026) (opens in a new tab)
  20. Cartesian Therapeutics K2 HealthVentures financing press release (2026) (opens in a new tab)
  21. Cartesian Therapeutics MG-001 clinical study protocol, version 4.2 (2024) (opens in a new tab)
  22. Cartesian Therapeutics MGFA 2024 presentation press release (2024) (opens in a new tab)
  23. Cartesian Therapeutics phase 2b 12-month results press release (2025) (opens in a new tab)
  24. Cartesian Therapeutics phase 2b topline results press release (2024) (opens in a new tab)
  25. Cartesian Therapeutics phase 2b updated results press release (2024) (opens in a new tab)
  26. Cartesian Therapeutics retreatment data press release (2026) (opens in a new tab)
  27. Cartesian Therapeutics RMAT designation press release (2024) (opens in a new tab)
  28. Cartesian Therapeutics second quarter 2026 results (2026) (opens in a new tab)
  29. Cartesian Therapeutics Special Protocol Assessment press release (2025) (opens in a new tab)
  30. Cartesian Therapeutics third quarter 2026 results (2026) (opens in a new tab)
  31. Cavalcante et al. (2024) (opens in a new tab)
  32. Centers for Medicare & Medicaid Services FY 2027 IPPS/LTCH PPS final rule (2026) (opens in a new tab)
  33. Chahin et al. (2025) (opens in a new tab)
  34. Choi et al. (2025) (opens in a new tab)
  35. Çipi et al. (2026) (opens in a new tab)
  36. Claytor et al. (2023) (opens in a new tab)
  37. ClinicalTrials.gov NCT04146051 (opens in a new tab)
  38. ClinicalTrials.gov NCT06193889 (opens in a new tab)
  39. ClinicalTrials.gov NCT06359041 (opens in a new tab)
  40. ClinicalTrials.gov NCT06799247 (opens in a new tab)
  41. ClinicalTrials.gov NCT06799247 record version 16 (opens in a new tab)
  42. ClinicalTrials.gov NCT07089121 (opens in a new tab)
  43. Dewilde et al. (2023a) (opens in a new tab)
  44. Dewilde et al. (2023b) (opens in a new tab)
  45. Dewilde et al. (2025a) (opens in a new tab)
  46. Dewilde et al. (2025b) (opens in a new tab)
  47. Di et al. (2024) (opens in a new tab)
  48. Dodd et al. (2025) (opens in a new tab)
  49. Dresser et al. (2021) (opens in a new tab)
  50. Engel-Nitz et al. (2018) (opens in a new tab)
  51. Epysqli prescribing information (2026) (opens in a new tab)
  52. EU Clinical Trials Information System 2024-520355-25-00 (opens in a new tab)
  53. FDA news release on CAR T cell REMS elimination (2025) (opens in a new tab)
  54. FDA Orphan Drug Designations and Approvals (2022) (opens in a new tab)
  55. FDA safety communication on CAR T cell REMS elimination (2025) (opens in a new tab)
  56. Fedak et al. (2026) (opens in a new tab)
  57. Furqan et al. (2024) (opens in a new tab)
  58. Gelinas et al. (2022) (opens in a new tab)
  59. Gilhus et al. (2019) (opens in a new tab)
  60. Gilhus et al. (2024) (opens in a new tab)
  61. Gilhus et al. (2026) (opens in a new tab)
  62. Granit et al. (2023) (opens in a new tab)
  63. Granit et al. supplementary appendix (2023) (opens in a new tab)
  64. Greco et al. (2024) (opens in a new tab)
  65. Greco et al. (2026) (opens in a new tab)
  66. Grob et al. (2008) (opens in a new tab)
  67. Gronseth et al. (2020) (opens in a new tab)
  68. Grover et al. (2026a) (opens in a new tab)
  69. Grover et al. (2026b) (opens in a new tab)
  70. Grover et al. (2026c) (opens in a new tab)
  71. Gusovsky Chevalier et al. (2025) (opens in a new tab)
  72. Gwathmey et al. (2026) (opens in a new tab)
  73. Habib et al. (2024) (opens in a new tab)
  74. Haghikia et al. (2023) (opens in a new tab)
  75. Harris et al. (2020) (opens in a new tab)
  76. Hegelmaier et al. (2026a) (opens in a new tab)
  77. Hegelmaier et al. (2026b) (opens in a new tab)
  78. Hehir and Silvestri (2018) (opens in a new tab)
  79. Herr et al. (2023) (opens in a new tab)
  80. Howard (2018) (opens in a new tab)
  81. Howard et al. (2017) (opens in a new tab)
  82. Howard et al. (2021) (opens in a new tab)
  83. Howard et al. (2023) (opens in a new tab)
  84. Howard et al. (2024) (opens in a new tab)
  85. Howard et al. (2026) (opens in a new tab)
  86. Huang et al. (2024) (opens in a new tab)
  87. Hughes et al. (2023) (opens in a new tab)
  88. ICER (2021) (opens in a new tab)
  89. ICER multiple myeloma final evidence report (2021) (opens in a new tab)
  90. Imaavy prescribing information (2026) (opens in a new tab)
  91. Jackson et al. (2023) (opens in a new tab)
  92. Jackson et al. (2025) (opens in a new tab)
  93. Jacob et al. (2025) (opens in a new tab)
  94. Jagannath et al. (2023) (opens in a new tab)
  95. Jiang et al. (2025) (opens in a new tab)
  96. Jul Jarbæk Nielsen et al. (2025) (opens in a new tab)
  97. Kaminski et al. (2024) (opens in a new tab)
  98. Katzberg et al. (2014) (opens in a new tab)
  99. Khateb et al. (2025) (opens in a new tab)
  100. Klygefa prescribing information (2026) (opens in a new tab)
  101. Kumar and Kim (2026a) (opens in a new tab)
  102. Kumar et al. (2026b) (opens in a new tab)
  103. Kusner et al. (2012) (opens in a new tab)
  104. Landfeldt et al. (2020) (opens in a new tab)
  105. Li et al. (2026) (opens in a new tab)
  106. Lien et al. (2024) (opens in a new tab)
  107. Lin et al. (2021) (opens in a new tab)
  108. Lord et al. (2026) (opens in a new tab)
  109. Lyman et al. (2020) (opens in a new tab)
  110. Managed Healthcare Executive eculizumab biosimilars article (2025) (opens in a new tab)
  111. Managed Healthcare Executive Uplizna IgG4-related disease approval article (2025) (opens in a new tab)
  112. Manolopoulos et al. (2025) (opens in a new tab)
  113. Massachusetts Executive Office of Health and Human Services Administrative Bulletin 24-19 (2024) (opens in a new tab)
  114. McLaren et al. (2026) (opens in a new tab)
  115. Meisel et al. (2026a) (opens in a new tab)
  116. Meisel et al. (2026b) (opens in a new tab)
  117. Mestinon prescribing information (2023) (opens in a new tab)
  118. Motte et al. (2024) (opens in a new tab)
  119. Muppidi et al. (2011) (opens in a new tab)
  120. Muppidi et al. (2022) (opens in a new tab)
  121. Myasthenia Gravis Foundation of America (opens in a new tab)
  122. Narayanaswami et al. (2021) (opens in a new tab)
  123. Narayanaswami et al. (2026a) (opens in a new tab)
  124. Narayanaswami et al. (2026b) (opens in a new tab)
  125. NCI Drug Dictionary (opens in a new tab)
  126. NCI Thesaurus (2026) (opens in a new tab)
  127. Nowak et al. (2025) (opens in a new tab)
  128. Parthan et al. (2024) (opens in a new tab)
  129. Patel et al. (2025) (opens in a new tab)
  130. Pesa et al. (2026a) (opens in a new tab)
  131. Pesa et al. (2026b) (opens in a new tab)
  132. Pharmaceutical Technology Descartes-08 net present value page (2024) (opens in a new tab)
  133. pharmaphorum Imaavy approval article (2025) (opens in a new tab)
  134. Phillips et al. (2022) (opens in a new tab)
  135. Pujades-Rodríguez et al. (2025) (opens in a new tab)
  136. Qi et al. (2025) (opens in a new tab)
  137. Reyes-Leiva et al. (2026) (opens in a new tab)
  138. Ribeiro et al. (2026) (opens in a new tab)
  139. Rodrigues et al. (2024) (opens in a new tab)
  140. Rousseff (2021) (opens in a new tab)
  141. Rystiggo prescribing information (2025) (opens in a new tab)
  142. Salari et al. (2021) (opens in a new tab)
  143. Sanders et al. (2016) (opens in a new tab)
  144. Sciancalepore et al. (2025) (opens in a new tab)
  145. Siddiqi et al. (2025) (opens in a new tab)
  146. Silvestri et al. (2026) (opens in a new tab)
  147. Smith et al. (2024) (opens in a new tab)
  148. Smith et al. (2026) (opens in a new tab)
  149. Soliris prescribing information (2026) (opens in a new tab)
  150. Suh et al. (2013) (opens in a new tab)
  151. Suzuki et al. (2026) (opens in a new tab)
  152. Tian et al. (2024) (opens in a new tab)
  153. Tice et al. (2022) (opens in a new tab)
  154. Ting et al. (2025) (opens in a new tab)
  155. Tse et al. (2025) (opens in a new tab)
  156. UCB RYSTIGGO pricing information (2025) (opens in a new tab)
  157. UCB ZILBRYSQ pricing information (2026) (opens in a new tab)
  158. Ultomiris prescribing information (2026) (opens in a new tab)
  159. Uplizna prescribing information (2025) (opens in a new tab)
  160. Vinciguerra et al. (2023) (opens in a new tab)
  161. Vissing et al. (2020) (opens in a new tab)
  162. Vu et al. (2022) (opens in a new tab)
  163. Vu et al. (2025) (opens in a new tab)
  164. Vu et al. (2026a) (opens in a new tab)
  165. Vu et al. (2026b) (opens in a new tab)
  166. Vyvgart Hytrulo prescribing information (2026) (opens in a new tab)
  167. Vyvgart prescribing information (2026) (opens in a new tab)
  168. Wolfe et al. (2016) (opens in a new tab)
  169. Wolfe et al. (2019) (opens in a new tab)
  170. Wong et al. (2025) (opens in a new tab)
  171. Wong et al. (2026) (opens in a new tab)
  172. Wu et al. (2024) (opens in a new tab)
  173. Ye et al. (2024) (opens in a new tab)
  174. Yoder et al. (2025) (opens in a new tab)
  175. Zhang et al. (2025) (opens in a new tab)
  176. Zhdanava et al. (2024) (opens in a new tab)
  177. Zilbrysq prescribing information (2026) (opens in a new tab)